High frequency of BRAFV600E mutations in ameloblastoma

Citations Over TimeTop 1% of 2013 papers

Abstract

Ameloblastoma is a benign but locally infiltrative odontogenic neoplasm. Although ameloblastomas rarely metastasise, recurrences together with radical surgery often result in facial deformity and significant morbidity. Development of non-invasive therapies has been precluded by a lack of understanding of the molecular background of ameloblastoma pathogenesis. When addressing the role of ERBB receptors as potential new targets for ameloblastoma, we discovered significant EGFR over-expression in clinical samples using real-time RT-PCR, but observed variable sensitivity of novel primary ameloblastoma cells to EGFR-targeted drugs in vitro. In the quest for mutations downstream of EGFR that could explain this apparent discrepancy, Sanger sequencing revealed an oncogenic BRAF V600E mutation in the cell line resistant to EGFR inhibition. Further analysis of the clinical samples by Sanger sequencing and BRAF V600E-specific immunohistochemistry demonstrated a high frequency of BRAF V600E mutations (15 of 24 samples, 63%). These data provide novel insight into the poorly understood molecular pathogenesis of ameloblastoma and offer a rationale to test drugs targeting EGFR or mutant BRAF as novel therapies for ameloblastoma.

Related Papers

• → Molecular biology exploration and targeted therapy strategy of Ameloblastoma(2022)17 cited
• → An immunohistochemical and genetic study of BRAFV600E mutation in Japanese patients with ameloblastoma(2020)27 cited
• → Molecular testing for BRAF V600 mutations in the BRIM-2 trial of the BRAF inhibitor vemurafenib in metastatic melanoma.(2011)5 cited
• → CHARACTERISTIC OF AMELOBLASTOMA IN ORAL AND MAXILLOFACIAL SURGERY AT HASAN SADIKIN HOSPITAL : 2 YEARS RETROSPECTIVE STUDY(2021)2 cited
• → BRAF V600E Mutation Test in Fine Needle Aspiration (FNA) Specimens of Thyroid Nodules by Competitive Allele-Specific TaqMan PCR (castPCR)(2023)